TABLE 1

Clinical characteristics of the donors and idiopathic pulmonary arterial hypertension (IPAH) patients

DonorsIPAH patients
Lung samples1516
Age years41.7±13.234.1±10.6
Male/female10/55/11
Height cm175±9170±8
Weight kg73.6±9.961.2±13.3*
mPAP mmHg71.2±16.6
PVR dyn·sec·cm−51845±669
6MWD m280±187
NYHA classIII–IV
NT-proBNP pg·mL−14412±2445
CRP mg·dL−11.2±2.4
PAH targeted therapy
 ERA1
 ERA+PDE5i1
 sGCs+PGI1
 PDE5i+PGI4
 ERA+PDE5i+PGI7
 PDE5i+PGI+CCB1
 Unknown1

Data are presented as n or mean±sd. mPAP: mean pulmonary arterial pressure; PVR: pulmonary vascular resistance; 6MWD: 6-min walking distance; NYHA: New York Heart Association; NT-proBNP: N-terminal pro-brain natriuretic peptide; CRP: C-reactive protein; ERA: endothelin receptor antagonists; PDE5i: phosphodiesterase type 5 inhibitor; sGCs: soluble guanylate cyclase stimulator; PGI: prostacyclin analogue; CCB: calcium channel blocker. *: p≤0.05.